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Abstract
We have established previously that minor subpopulations of cells with stable differences in their intrinsic mitochondrial
membrane potential (Dym) exist within populations of mammary and colonic carcinoma cells and that these differences in
Dym are linked to tumorigenic phenotypes consistent with increased probability of participating in tumor progression.
However, the mechanism(s) involved in generating and maintaining stable differences in intrinsic Dym and how they are
linked to phenotype are unclear. Because the mucin 1 (MUC1) oncoprotein is over-expressed in many cancers, with the
cytoplasmic C-terminal fragment (MUC1 C-ter) and its integration into the outer mitochondrial membrane linked to
tumorigenic phenotypes similar to those of cells with elevated intrinsic Dym, we investigated whether endogenous
differences in MUC1 levels were linked to stable differences in intrinsic Dym and/or to the tumor phenotypes associated
with the intrinsic Dym. We report that levels of MUC1 are significantly higher in subpopulations of cells with elevated
intrinsic Dym derived from both mammary and colonic carcinoma cell lines. However, using siRNA we found that down-
regulation of MUC1 failed to significantly affect either the intrinsic Dym or the tumor phenotypes associated with increased
intrinsic Dym. Moreover, whereas pharmacologically mediated disruption of the Dym was accompanied by attenuation of
tumor phenotype, it had no impact on MUC1 levels. Therefore, while MUC1 over-expression is associated with
subpopulations of cells with elevated intrinsic Dym, it is not directly linked to the generation or maintenance of stable
alterations in intrinsic Dym, or to intrinsic Dym associated tumor phenotypes. Since the Dym is the focus of
chemotherapeutic strategies, these data have important clinical implications in regard to effectively targeting those cells
within a tumor cell population that exhibit stable elevations in intrinsic Dym and are most likely to contribute to tumor
progression.
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Introduction
Heterogeneity is a fundamental property of cellular systems,
including solid tumors [1], where diversity likely provides
reservoirs of cells which, through evasion of preventative or
therapeutic intervention and/or tolerance and rapid response to
shifting micro-environmental conditions, can participate in tumor
expansion and progression. Our previous work has established that
within populations of colonic and mammary carcinoma cells there
are minor subpopulations of cells that exhibit stable differences in
intrinsic mitochondrial membrane potential (Dym) which are
linked to tumorigenic phenotypes [1,2]. Although the mechanisms
involved in generating and maintaining differences in Dym are
unclear, they may reflect alterations in mitochondrial membranes
[3–8] (Mariadason & Heerdt, unpublished).
The mucin 1 (MUC1) oncoprotein is a highly O-glycosylated
heterodimeric, type-I transmembrane glycoprotein that is over-
expressed in many cancers [9,10]. MUC1 is synthesized as a single
polypeptide which is cleaved into an N-terminal extra cellular
fragment (MUC1 N-ter) and a C-terminal fragment (MUC1 C-
ter), which includes transmembrane and cytoplasmic domains.
Glycosylation allows MUC1 N-ter to be transported to the cell
surface where it is tethered by dimerization with MUC1 C-ter.
The cytoplasmic domain of MUC1 C-ter (MUC1-CD) interacts
with diverse signal transducing molecules [9,11–14], and has been
linked to transcriptional regulation of various genes [15,16]
including VEGF [15–17]. Additionally, MUC1 C-ter is targeted
to the mitochondria, where it integrates into the outer mitochon-
drial membrane [13,14]. Mitochondrial (mt)-associated MUC1 C-
ter has been reported to attenuate dissipation of the Dym and
subsequent apoptosis initiated through the intrinsic (mitochondrial
mediated) pathway [13–15,18–21].
Because MUC1 is over-expressed by most human carcinomas,
where it is associated with tumor progression and poor prognosis
[22], we asked whether constitutive levels of MUC1 were linked to
stable differences in intrinsic Dym and, as a consequence, were a
component or maker of tumor cell heterogeneity in colonic and/or
mammary carcinoma cell populations. Using an siRNA approach,
we then investigated the impact of diminished levels of MUC1 on
intrinsic Dym and on Dym linked tumorigenic phenotypes
including cellular sensitivity to butyrate (NaB) mediated apoptosis
and constitutive hypoxia-independent VEGF secretion. Finally, we
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on MUC1 and hypoxia-independent VEGF secretion levels. Our
data demonstrate that while elevated constitutive MUC1 is
associated with subpopulations of cells with elevated intrinsic
Dym, MUC1 is not directly linked to the generation or maintenance
of stable alterations in intrinsic Dym, or to intrinsic Dym
associated tumor phenotypes.
Chemotherapeutic strategies that preferentially target cells with
relatively higher intrinsic Dym have been investigated and some
clinical responses reported [23–33]. Based on the data presented
here, exploitation of stable elevation in intrinsic Dym may be a
novel and efficacious way to target cells within tumor populations
that are the most likely to contribute to tumor expansion and
progression [1,2].
Materials and Methods
Cell Culture
The SW620 and SW480 human colonic carcinoma cell lines,
and the MCF7 human mammary carcinoma cell line, were
obtained from the American Type Culture Collection. Subcloned
cell lines were derived as described [1,2].
qRT-PCR
Total RNA was purified using Qiagen RNEasy kit (Qiagen,
Valencia, CA). cDNA was synthesized using Superscript III First-
Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA).
MUC1 expression was measured by RT-PCR using Gene
Expression Assay (Applied Biosystems, Carlsbad, CA). Expression
was normalized to GAPDH.
Immunoblotting
Mitochondrial enriched fractions and S-10 Post Mitochondrial
Fractions (PMF), containing cytoplasmic proteins and light
membranes, were prepared as described [34,35], size-fractionated
on 4–20% acrylamide SDS-PAGE gels (Bio-Rad, Hercules, CA)
and blotted onto PVDF membranes (Amersham, Arlington
Heights, IL). Blots were incubated with anti-MUC1 C-ter
(Labvision Ab-5 (MH1; CT2)) and anti-porin (VDAC; Calbio-
chem; Ab-5) followed by appropriate secondary antibodies.
Reactions were detected by Enhanced Chemiluminescence Plus
reagents (Amersham) and quantified by densitometry using Kodak
IS4000R and Kodak Molecular Imaging Software.
Transfection
Cells were seeded at 5610
5 cells/well in 6 well plates and
allowed to grow overnight. The following day cells were either left
untreated, mock transfected, transfected with ON-TARGET Plus
non-targeting (NT) siRNA pool (Dharmacon, Lafayette, CO), or
MUC1 ON-TARGET Plus Smart Pool siRNA (Dharmacon,
Lafayette, CO). Transfections were performed using Lipofecta-
mine RNAiMAX (Invitrogen, Carlsbad, CA) and Opti-MEM
reduced serum medium (Invitrogen, Carlsbad, CA).
Quantitation of cell surface MUC1 N-ter
Cells were stained with FITC-conjugated anti-human MUC1
(CD227) monoclonal antibody (BD Pharmingen) and the percent-
age of stained cells and staining intensity were quantified by flow
cytometry.
Quantitation of Dym and apoptosis
Mitochondrial membrane potential was determined by flow
cytometry using the Dym-dependent fluorescent dye JC-1
(5,596,69-tetrachloro-1,19,3,39 tetraethylbenzimidazol carbocyani-
neiodide; Molecular Probes, Eugene, OR), analyzed as we have
previously described [1,35–38]. Apoptosis was determined by
propidium iodide (PI) staining and flow cytometry, as we have
described [35,38,39].
Quantitation of vascular endothelial growth factor (VEGF)
Conditioned tissue culture medium was harvested for quanti-
tation of VEGF165 protein by ELISA (R&D Systems, Inc.,
Minneapolis, MN) according to the manufacturer’s protocol.
The reduction of MTT to formazan [40], combined with a
standard curve generated by serial dilution of SW620 cells, was
used to determine the number of cells/well and standardize for
variations in cell number among wells [41].
Pharmacologic modulation of Dym
We have previously shown that exposure of SW620 cells to the
K
+ ionophore valinomycin results in a sustained disruption the
Dym [35,38]. Thus, following overnight treatment with 5 mM
valinomycin, cells were stained with JC-1 or FITC-conjugated
anti-human MUC1 (CD227) and analyzed by flow cytometry for
quantitation of Dym and cell surface MUC1 N-ter, respectively.
Levels of MUC1 C-ter were determined in mitochondrial enriched
fractions by immunoblotting and levels of VEGF165 were
quantified in harvested cconditioned tissue culture medium (as
described above).
Statistical analyses
Data from at least 3 independent determinations were
compared by Bonferroni’s multiple comparison tests. Mean data
were also evaluated as a function of the intrinsic Dym, determined
by JC-1 staining, using linear regression analyses [1,36,41].
Results
Constitutive MUC1 levels are associated with stable
differences in intrinsic Dym of subcloned cell lines
derived from colonic and mammary carcinoma cell
populations
MUC1 over-expression is associated with tumor progression
and poor prognosis [22] and is reported to diminish apoptosis
signalled through the intrinsic pathway [13–15,18–20] and
enhance VEGF expression in some cancer cells in vitro
[17,42,43] – cellular activities that we have linked to differences
in intrinsic Dym of subcloned mammary and colonic carcinoma
cell lines [1,2,41]. Therefore, we investigated the potential
relationship between MUC1 levels and intrinsic Dym.
Steady state mRNA levels of MUC1 were determined by qRT-
PCR in the parental population of SW620 human colonic
carcinoma cells and in subcloned cell lines derived from SW620
cells that have stable intrinsic Dym ranging from higher,
comparable or lower than that of the population (qDym,
<Dymo rQDym, respectively) [1]. As shown in Figure 1A,
MUC1 mRNA levels are at least 1.5 fold, and as much as 6 fold,
higher in the subcloned cell lines with elevated Dym
(*P,0.001 vs. the population of SW620 cells).
To investigate whether this relationship between MUC1 mRNA
and intrinsic Dym extended to MUC1 C-ter protein levels,
mitochondrial (mt) and accompanying Post Mitochondrial (PMF)
enriched fractions were isolated from the SW620 colonic
carcinoma cell population and from subcloned lines derived from
SW620 cells with a range of relative intrinsic Dym [1].
Immunoblots of mt and PMF were probed with antibodies
Mitochondrial Membrane Potential, Phenotype, MUC1
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e25207Figure 1. Constitutive MUC1 levels are associated with stable differences in intrinsic Dym of subcloned cell lines derived from
SW620 colonic carcinoma cell population. A: Steady state mRNA levels of MUC1 were determined by qRT-PCR, normalized to GAPDH, in the
parental population of SW620 cells and in subcloned cell lines derived from SW620 cells that have a range stable intrinsic Dym. (*; P,0.001 vs. the
population of SW620 cells.) B: Immunoblots of mt and PMF from the SW620 colonic carcinoma cell population and from subcloned lines derived from
SW620 cells with intrinsic Dym higher (qDym), lower (QDym) and comparable (<Dym) to that of the population were probed with anti-MUC1 C-
ter and anti-VDAC and chemiluminescence signals quantified and expressed as a function of the intrinsic Dym, determined by JC-1 staining, using
linear regression analyses. MUC1 C-ter, but not VDAC, levels in both mt enriched and PMF are significantly associated with the intrinsic Dym
(P=0.0053 and 0.0032, respectively).
doi:10.1371/journal.pone.0025207.g001
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C-ter) or the mt outer membrane protein VDAC, and chemilu-
minescence signals quantified and expressed as a function of the
intrinsic Dym, determined by staining cells with the Dym-
dependent dye JC-1, using linear regression analyses. As shown in
Figure 1B, while MUC1-C-ter levels in both mt enriched and
PMF are significantly associated with the intrinsic Dym
(P=0.0053 and 0.0032, respectively), VDAC levels in neither
the mt nor the PMF fractions are linked to intrinsic Dym. This
relationship between MUC1 C-ter and intrinsic Dym of subcloned
cells lines derived from SW620 cells was confirmed by analyses of
multiple immunoblots (not shown).
We next asked whether the association between intrinsic Dym
and levels of endogenous mt-associated MUC1 C-ter were unique
to subclones derived from SW620 colonic carcinoma cells. Thus,
we investigated subcloned cell lines with stable differences in
intrinsic Dym that were derived from the SW480 and MCF7
human colonic and mammary carcinoma cell lines, respectively.
Similar to the subclones derived from SW620 cells, the SW480
and MCF7 derived subcloned cell lines exhibit intrinsic Dym-
linked tumorigenic phenotypes consistent with enhanced proba-
bility to participate in local tumor expansion [2]. Mitochondrial
enriched fractions were isolated from the parental populations of
SW480 and MCF7 cells and from accompanying derived
subcloned cell lines with intrinsic Dym ranging from significantly
lower to significantly higher than that of the population. Mt-
associated MUC1 C-ter levels were then determined by immuno-
blotting and expressed as a function of the relative intrinsic Dym
using linear regression analyses. As shown in Figure 2, constitutive
levels of mt-associated MUC1 C-ter are significantly linked to the
intrinsic Dym of subclones established from SW480 colonic, and
MCF7 mammary, carcinoma cells (2A and 2B;; P=0.0118 and
0.021, respectively), thereby supporting the relationship between
the Dym and mt associated MUC1 C-ter in cancer cells.
siRNA mediated down-regulation of MUC1 does not
affect intrinsic Dym
Although the levels of mt-associated MUC1 C-ter are linked to
the intrinsic Dym of cancer cells and MUC1 C-ter has been
reported to integrate into the outer mitochondrial membrane
[13,14], it is unclear whether mitochondrial MUC1 C-ter
contributes to regulation or maintenance of the Dym [21]. To
investigate this, the SW620 cell population and derived subcloned
cell lines with a range of relative intrinsic Dyms (QDym, <Dym
and qDym) were mock transfected, or transfected with non-
targeting (NT) or MUC1 siRNA. Twenty-four, 48 and 72 hours
later MUC1 mRNA levels were determined by qRT-PCR
(Figure 3). Compared to mock or NT-siRNA transfected cells,
MUC1 expression levels were down regulated approximately 40%
to 60% 24 hours after transfection of MUC-siRNA. Interestingly,
the most extensive decrease in MUC1 expression was seen in the
subclone with elevated Dym, in which the original levels of MUC1
were the highest. siRNA-induced down regulation of MUC1
mRNA was maintained 48 and at 72 hours after transfection and,
in fact, continued to decrease in each cell line at each time point
by approximately 10%, achieving approximately 87% lower levels
of MUC1 mRNA in the subclone with elevated intrinsic Dym
after 72 hours. Importantly, although MUC1 expression was not
completely silenced, levels in the subclone with elevated intrinsic
Dym were comparable to those of the mock transfected
population of SW620 cells 48 and 72 hours following MUC1-
siRNA transfection MUC1 expression (P.0.05).
Because MUC1 mRNA levels in the siRNA-MUC1 transfected
subclone with elevated Dym approximated those of the mock
transfected population of SW620 cells, we focused on these two
cell lines in subsequent investigations. Thus, cells were mock, NT-
siRNA or MUC1-siRNA transfected and 24, 48 and 72 hours
later relative levels of cell surface MUC1 N-ter and mt-associated
MUC1 C-ter were determined by flow cytometry and immuno-
blotting, respectively. As shown in Figure 4, siRNA-mediated
Figure 2. Constitutive mt-associated MUC1 C-ter levels are
associated with stable differences in intrinsic Dym of sub-
cloned cell lines derived from SW480 colonic and MCF7
mammary carcinoma cell populations. Mt-associated MUC1 C-ter
levels were determined by immunoblotting in mt enriched fractions
isolated from the population of SW480 (A) and MCF7 (B) cells and from
subclones derived from these cell populations that have stable intrinsic
Dym ranging from significantly lower to significantly higher than that
of the population. MUC1 C-ter levels are expressed as a function of the
relative intrinsic Dym by linear regression analyses.
doi:10.1371/journal.pone.0025207.g002
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in cell surface MUC1 N-ter and mt associated MUC1 C-ter in
both cell lines at each time point following transfection (4A and
4B, respectively). Moreover, although not completely eliminated,
consistent with the siRNA induced reduction of MUC1 mRNA
(Figure 3), the levels of MUC1 N-ter surface staining and mt-
associated MUC1 C-ter in MUC1-siRNA transfected cells with
elevated intrinsic Dym were comparable to those of mock
transfected population of SW620 cells at each time point
(P.0.05). Therefore, siRNA-induced down regulation of MUC1
mRNA is reflected in coincidently diminished levels of cell surface
MUC1 N-ter and mt-associated MUC1 C-ter, especially in cells
with relatively high intrinsic Dym.
We next investigated how siRNA mediated down regulation of
MUC1 affected the Dym. Twenty-four, 48 and 72 hours following
mock, NT-siRNA or MUC1-siRNA transfection, cells were
stained with JC-1 and analyzed by flow cytometry [1,35–38]. As
shown in figure 4C, siRNA induced reduction of MUC1 had no
effect on the Dym of either cell line at any time points evaluated.
Therefore, despite comparable levels of MUC1 mRNA, cell
surface MUC1 N-ter and mt-associated MUC1 C-ter in the
subclone with elevated intrinsic Dym and mock transfected
population of SW620 cells – particularly 48 and 72 hours after
MUC1-siRNA transfection-the relatively higher intrinsic Dym
was maintained. Similarly, siRNA mediated down regulation had
no impact on the Dym of additional SW620 derived subcloned
cell lines with intrinsic Dym ranging from lower to higher than
that of the population (not shown). Thus, it is unlikely that MUC1
levels play a role in the regulation or maintenance of stable
difference in intrinsic Dym.
siRNA mediated down-regulation of MUC1 does not
affect intrinsic Dym-linked sensitivity to butyrate (NaB)
induced apoptosis
Over-expression of MUC1 has been reported to attenuate
dissipation of the Dym and subsequent apoptosis induced
through the intrinsic (mitochondrial-mediated) pathway [13–
15,18–21]. Our previous work [1,36,38] has shown that the
Dym, and the process of Dym dissipation, play critical roles in
initiation of the intrinsic apoptotic pathway induced by the
physiological relevant [44], chemoprotective [45–48] short chain
fatty acid butyrate (NaB). Furthermore, we have shown that
Figure 3. MUC1 siRNA-mediates down regulation of MUC1 expression in subcloned cell lines with different intrinsic Dym. Subcloned
cell lines with intrinsic Dym higher (qDym), lower (QDym) and comparable (<Dym) to that of the population, and the SW620 parental population,
were mock transfected, or transfected with NT- or MUC1-siRNA. Twenty-four, 48 and 72 hours later levels of MUC1 mRNA were determined by qRT-
PCR, normalized to GAPDH. The level of MUC1 mRNA in the siRNA-MUC1 transfected cell line with qDym did not differ significantly from that of
mock transfected SW620 cell population 48 and 72 hours after transfection (P.0.05).
doi:10.1371/journal.pone.0025207.g003
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either colonic or mammary cancer cell populations, are less
sensitive to NaB mediated cytotoxicity than cells with lower Dym
[1,2,41].
To investigate the impact of siRNA mediated down regulation
of MUC1 on NaB induced apoptosis, the population of SW620
cells and derived subclone with elevated intrinsic Dym were mock,
NT-siRNA or MUC1-siRNA transfected. Forty-eight hours later,
a time point at which the MUC1 levels in two cell lines are
comparable (Figures 3 and 4A and 4B), cells were exposed to 5mM
NaB, a physiologically relevant concentration [49,50], for
48 hours, a time point at which we have shown induction of
significant apoptosis [1,36,38]. Cells were then stained with PI and
the percentage of apoptotic cells determined by flow cytometry. As
shown in Figure 5, down regulation of MUC1 did not significantly
impact NaB mediated apoptosis in either cell line, and, consistent
with the absence of an effect on intrinsic Dym (Figure 4C),
decreased sensitivity to NaB was retained in MUC1-siRNA
transfected cells with elevated intrinsic Dym.
siRNA mediated down-regulation of MUC1 does not
affect intrinsic Dym-linked constitutive hypoxia-
independent VEGF secretion
We have previously shown a significant association between the
intrinsic Dym and levels of steady state, hypoxia-independent
VEGF secretion in subcloned cell lines derived from mammary
and colonic carcinoma cells [1,2,41]. Because the cytoplasmic
domain of MUC1 C-ter (MUC1-CD) has been linked to
transcriptional regulation of VEGF [15–17] and our data show
that the levels of MUC1 C-ter in the PMF – which encompasses
cytoplasmic components - are related to the intrinsic Dym
(Figure 1B), we investigated the effect of siRNA induced MUC1
down regulation on steady state VEGF secretion in colonic
Figure 4. siRNA-mediated down regulation of MUC1 N-ter and mt-associated C-ter levels does not affect the Dym. Cells were mock,
MUC1- or NT-siRNA transfected. Twenty-four, 48 and 72 hours later, levels of cell surface MUC1 N-ter were determined by flow cytometry (A); levels of
mt-associated MUC1 C-ter determined by quantitative immunoblotting (B) and the Dym was determined by JC-1 staining and flow cytometry.
doi:10.1371/journal.pone.0025207.g004
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transfection, a time point at which the MUC1 levels in cells with
elevated Dym are comparable to those in mock transfected cells
with lower intrinsic Dym (Figures 3 and 4A and 4B), conditioned
tissue culture medium was harvested and levels of VEGF were
determined. Similar to the absence of effects on intrinsic Dym
(Figure 4C) or NaB induced apoptosis (Figure 5) down regulation
of MUC1 did not significantly affect constitutive hypoxia-
independent VEGF secretion levels in either cell line, with the
relatively higher level of secretion retained in MUC1-siRNA
transfected cells with elevated intrinsic Dym (Figure 6).
Pharmacologically mediated disruption of the Dym
does not affect MUC1 levels but attenuates intrinsic
Dym-linked constitutive hypoxia-independent VEGF
secretion
Finally, to investigate the impact of disruption of the intrinsic
Dym on MUC1 and constitutive hypoxia-independent VEGF
secretion levels, the population of SW620 cells and derived
subclone with elevated intrinsic Dym were exposed to the K
+
ionophore valinomycin to dissipate the Dym [35,38]. The Dym,
secreted VEGF, MUC1 N-ter and MUC1 C-ter levels were then
determined. As shown in Figure 7A, whereas valinomycin
treatment resulted in decreases in the Dym of both cell lines by
at least 90%, accompanied by significantly decreased constitutive
VEGF secretion levels (#, P,0.05), neither cell surface MUC1 N-
ter nor mt-associated MUC1- C-ter (Figure 7B) levels were
impacted in either cell line by disruption of the Dym. Thus, it is
likely that the intrinsic Dym and associated tumor phenotype are
independent of MUC1 over-expression in colonic carcinoma cells.
Discussion
Heterogeneity among cells is a fundamental property of tumors
and likely allows for selection of subpopulation phenotypes that
have an increased probability of participating in subsequent tumor
progression [51]. Whereas the origins of, and the mechanisms by
which, cellular heterogeneity contributes unequally to tumorigen-
esis are unclear [51], it has been know for some time that the
population average Dym of cancer cells is significantly higher than
that of normal cells ([24,52–55] and that mitochondria are
important and critical elements in establishing tumorigenic
phenotype [56].
Using single cell subclones, our previous work has established
the existence of subpopulations of cells within mammary and
colonic carcinoma cell populations that, compared to the
population average Dym, have stable elevations in their intrinsic
Dym [1,2]. Moreover, we have shown that these elevations in
intrinsic Dym are linked to tumor phenotypes associated with
increased probability of tumor progression [1,2]. Because MUC1
is over-expressed in many human carcinomas and cell lines where
it is also associated with tumor progression [9,22], we investigated
the relationship between intrinsic Dym and endogenous MUC1
expression. We found that constitutive MUC1 levels are
significantly associated with stable differences in intrinsic Dym
of subcloned cell lines derived from colonic and mammary
carcinoma cell populations, with higher levels of MUC1 exhibited
in cells with elevated intrinsic Dym. However, we also found that
siRNA-induced down-regulation of MUC1 in colonic carcinoma
cells with elevated intrinsic Dym to levels comparable to those in
cells with lower Dym does not affect the intrinsic Dymo rDym-
linked tumor phenotypes, including the decreased sensitivity to
chemoprotective NaB induced apoptosis and the increased
constitutive, hypoxia-independent VEGF secretion that are
characteristic of cells with elevated intrinsic Dym [1,2]. Addition-
ally, we found that chemically induced disruption of the Dym was
associated with decreased levels of constitutive hypoxia-indepen-
dent VEGF secretion, but had no impact on MUC1 levels.
Therefore, these data suggest that over-expression of MUC1 is not
directly involved in the generation or maintenance of stable
alterations in intrinsic Dym and Dym linked phenotypes, and that
Figure 5. siRNA mediated down-regulation of MUC1 does not affect intrinsic Dym-linked sensitivity to butyrate (NaB) induced
apoptosis. Cells were mock, MUC1- or NT-siRNA transfected and 48 hours later and then exposed to 5 mM NaB for 24 hours. Percentage of
apoptotic cells was determined by PI staining and flow cytometry.
doi:10.1371/journal.pone.0025207.g005
Figure 6. siRNA mediated down-regulation of MUC1 does not
affect intrinsic Dym-linked constitutive hypoxia-independent
VEGF secretion. Cells were mock, MUC1- or NT-siRNA transfected and
48 hours later VEGF secretion levels were determined in harvested
conditioned tissue culture medium.
doi:10.1371/journal.pone.0025207.g006
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dent of MUC1 over-expression in colonic carcinoma cells.
The higher average Dym in cancer cells [24,52–55] has been
used as a rationale to develop compounds that accumulate in
the mt based on the Dym (i.e., mitochondriotropic agents) to
preferentially kill tumor cells [23–33]. Because mitochondrio-
tropic agents accumulate in the mitochondrial matrix at a 10-
fold higher level with each 60 mV increase in Dym [57], they
have the potential of being particularly efficacious in targeting
cells with modest elevations in the intrinsic Dym-the specific
cells within the tumor cell population that our data show are
the most likely to participate in tumor expansion and pro-
gression [1,2].
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Figure 7. Pharmacologically mediated disruption of the Dym does not affect MUC1 levels but attenuates intrinsic Dym-linked
constitutive hypoxia-independent VEGF secretion. Cells were exposed to 5 mM valinomycin overnight and then stained with JC-1 or FITC-
conjugated anti-human MUC1 (CD227) and analyzed by flow cytometry for quantitation of Dym and cell surface MUC1 N-ter, respectively. Levels of
VEGF165 were quantified in conditioned tissue culture medium harvested from untreated and valinomycin treated cells (#; P,0.05 valinomycin vs.
untreated) (A). Levels of MUC1 C-ter were determined in mitochondrial enriched fractions by immunoblotting (B).
doi:10.1371/journal.pone.0025207.g007
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